Osaic Holdings
NBIX icon

Osaic Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Osaic Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.81M Buy
22,617
+19,921
+739% +$2.96M ﹤0.01% 1753
2026
Q1 		$355K Sell
2,696
-481
-15% -$63.8K ﹤0.01% 3670
2025
Q4 		$451K Sell
3,177
-1,205
-27% -$175K ﹤0.01% 3428
2025
Q3 		$615K Sell
4,382
-649
-13% -$87.9K ﹤0.01% 3259
2025
Q2 		$618K Buy
5,031
+740
+17% +$84.9K ﹤0.01% 2945
2025
Q1 		$475K Buy
4,291
+541
+14% +$68.5K ﹤0.01% 2926
2024
Q4 		$512K Sell
3,750
-2,298
-38% -$284K ﹤0.01% 2778
2024
Q3 		$697K Buy
6,048
+173
+3% +$23.7K ﹤0.01% 2569
2024
Q2 		$809K Sell
5,875
-7,975
-58% -$1.09M ﹤0.01% 2366
2024
Q1 		$1.91M Buy
13,850
+4,198
+43% +$573K ﹤0.01% 1730
2023
Q4 		$1.27M Buy
9,652
+141
+1% +$16.2K ﹤0.01% 2273
2023
Q3 		$1.07M Buy
9,511
+2,070
+28% +$218K ﹤0.01% 2579
2023
Q2 		$702K Sell
7,441
-5,419
-42% -$529K ﹤0.01% 2845
2023
Q1 		$1.3M Sell
12,860
-763
-6% -$79.4K ﹤0.01% 2211
2022
Q4 		$1.63M Sell
13,623
-231
-2% -$27.1K ﹤0.01% 1925
2022
Q3 		$1.47M Buy
13,854
+3,529
+34% +$358K ﹤0.01% 1875
2022
Q2 		$1.01M Buy
10,325
+279
+3% +$25.8K ﹤0.01% 2259
2022
Q1 		$1.06M Buy
10,046
+858
+9% +$72.7K ﹤0.01% 2520
2021
Q4 		$784K Sell
9,188
-1,112
-11% -$102K ﹤0.01% 2623
2021
Q3 		$990K Buy
10,300
+953
+10% +$90K ﹤0.01% 2356
2021
Q2 		$910K Buy
9,347
+477
+5% +$45.7K ﹤0.01% 2450
2021
Q1 		$863K Buy
8,870
+987
+13% +$103K ﹤0.01% 2368
2020
Q4 		$755K Sell
7,883
-426
-5% -$41.1K ﹤0.01% 2281
2020
Q3 		$807K Buy
8,309
+3,850
+86% +$445K ﹤0.01% 2009
2020
Q2 		$531K Sell
4,459
-2,404
-35% -$266K ﹤0.01% 2299
2020
Q1 		$243K Buy
+6,863
New +$672K ﹤0.01% 2716

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Osaic Holdings's NBIX Position: Q2 2026 in Review

Osaic Holdings increased its Neurocrine Biosciences (NBIX) stake by 739% in Q2 2026, buying an estimated $2.96M and bringing the position to 22,617 shares worth $3.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

Osaic Holdings first reported a position in NBIX in Q1 2020 and has held it in 26 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Osaic Holdings held 22,617 shares of Neurocrine Biosciences worth $3.81M as of Q2 2026.
  • Osaic Holdings bought 19,921 Neurocrine Biosciences shares in Q2 2026, an estimated $2.96M.
  • Neurocrine Biosciences made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #1753 holding.
  • Osaic Holdings first reported a position in Neurocrine Biosciences in Q1 2020 and has held it in 26 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.